How do you approach treatment for ovarian carcinosarcoma that has progressed during adjuvant carboplatin, paclitaxel, and bevacizumab following optimal tumor reductive surgery?

How do you approach treatment for ovarian carcinosarcoma that has progressed during adjuvant carboplatin, paclitaxel, and bevacizumab following optimal tumor reductive surgery?

• Taxane cytotoxic chemotherapy
• Topoisomerase cytotoxic chemotherapy
• Gemcitabine
• Liposomal doxorubicin
• Cyclophosphamide
• Doxorubicin
• Platinum cytotoxic chemotherapy
• PD-1/PD-L1 inhibitor (if PD-L1+, MSI-H, or TMB-H)
• Hormonal therapy (if ER/PR+)
• PARP inhibitor (if HRD/LOH+)
• Other targeted therapy
• Other cytotoxic chemotherapy